London · Delayed Price · Currency is GBP · Price in GBX Dr. Martens Earnings Call Transcripts
Fiscal Year 2026
-
Q3 saw accelerated growth in the Americas, strong wholesale gains across all regions, and robust performance in shoes, while EMEA retail lagged due to a tough consumer environment. Inventory and cost controls remain strong, and early U.S. price increases show no negative impact.
-
Revenue and profit improved year-on-year, driven by higher full-price sales, cost control, and growth in the Americas and APAC. Strategic execution is on track, with new product launches, expanded partnerships, and technology investments supporting future growth.
Fiscal Year 2025
-
A new consumer-first strategy aims to drive sustainable, profitable growth by broadening product offerings, optimizing market-specific distribution, and leveraging brand strengths. Financial discipline, operational improvements, and technology investments support mid to high teens EBIT margin targets over the medium term.
-
Stabilization achieved with all key objectives met, including Americas DTC growth, cost reduction, and significant inventory and debt reduction. Revenue and profit declined YoY but were in line with guidance, and the business is positioned for future growth.
-
Q3 results met expectations with USA DTC up 4% and APAC strong, while EMEA was flat due to less discounting. Guidance is unchanged, inventory is down, and cost savings are on track. Product-led marketing and new products are driving positive momentum.
-
First half results met expectations with revenue down 16% and gross margin stable year-on-year. Cost savings, inventory reduction, and refinancing strengthened the balance sheet, while product-focused marketing and DTC improvements set the stage for H2 growth.